France has established itself as a cornerstone of the European Antibody-Drug Conjugate (ADC) landscape, distinguished by a unique integration of high-tier academic research and a rapidly maturing biotech ecosystem. Centred around major clusters in Paris-Saclay, Lyon, Marseille, and Le Mans the French ADC sector excels in two specific areas: linker chemistry innovation and early-phase clinical translation.

The ecosystem is anchored by world-renowned clinical institutions like Gustave Roussy and Institut Curie, which serve as global hubs for testing next-generation ADC candidates. While home-grown pioneers like Mablink Bioscience (acquired by Eli Lilly) and Innate Pharma lead in technological breakthroughs, international giants such as AstraZeneca, Gilead, and Pfizer heavily rely on the French clinical network to spearhead their European trial enrollment. This synergy between "bench and bedside" makes France a critical destination for solving the industry's most pressing challenges in ADC stability and therapeutic window optimisation.